Imugene (ASX: IMU) — Company Overview, News & Financial Data
Imugene is a clinical-stage immuno-oncology company developing T-cell receptor therapies and oncolytic virotherapies for cancer treatment.
Imugene
Imugene is a clinical-stage immuno-oncology biotechnology company focused on developing novel cancer therapies designed to harness the immune system to treat B-cell malignancies and solid tumors. The company's platform includes allogeneic chimeric antigen receptor T-cell therapies, oncolytic viruses, and cancer immunotherapies. Its clinical pipeline features off-the-shelf cellular therapeutics such as azercabtagene zapreleucel, targeting CD19-expressing blood cancers, along with proprietary oncolytic virus technologies like CF33 and B-cell immunotherapy platforms. Imugene conducts clinical trials across novel targets to provide therapeutic options for patients with advanced or refractory cancers.
Snapshot
Operations
Products and/or services of Imugene
- Allogeneic Cell Therapies: Off-the-shelf cellular immunotherapy programs centered on azercabtagene zapreleucel targeting CD19 in Phase 1b clinical trials for B-cell malignancies and non-Hodgkin lymphoma to evaluate safety and clinical efficacy in patients.
- Oncolytic Virus Therapies: Engineered chimeric poxvirus platforms featuring VAXINIA and CHECKvacc constructs designed to selectively infect, replicate within, and lyse tumor cells while activating systematic antitumor immune responses across multiple solid tumor indications.
- B-Cell Immunotherapies: Active immunotherapeutic platforms including HER-Vaxx and PD1-Vaxx vaccine candidates engineered to stimulate the host immune system to generate polyclonal antibodies targeting specific cancer antigens such as HER2 and PD-1 pathways.
- Combination Tumor Platforms: Oncolytic virus technologies engineered to express CD19 targets on solid tumor cells, enabling CD19-directed CAR T cell therapies and targeted therapeutics to recognize and destroy previously untargetable solid tumor masses.
- Clinical Development Operations: Clinical trial management conducting Phase 1 and Phase 2 human trials across medical centers in Australia and North America to evaluate therapeutic safety, dosage escalation, and therapeutic efficacy across novel targets.
- Biopharmaceutical Licensing: Strategic licensing and collaborative research agreements for proprietary cell therapy and oncolytic virus platforms, supporting pre-clinical asset discovery, technology transfer, and commercialization pathways across global biopharmaceutical markets.
Imugene executive team
- Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExecutive Chairman
- Ms. Leslie ChongCEO, MD & Executive Director
- Mr. Darren Michael Keamy B.Com., CPACFO & Company Secretary
- Dr. John Byon M.D., Ph.D.Chief Medical Officer
- Ms. Ursula McCurryChief Clinical Operations Officer